China Biotech Manufacturer HighTide Therapeutics to IPO on Hong Kong Exchange on 22nd December 2023, Target to Raise $35.6 Million Instead of Planned $200 Million
14th December 2023 | Hong Kong
China biotech manufacturer HighTide Therapeutics is planning to IPO on Hong Kong Exchange (HKEX) on 22nd December 2023, targeting to raise $35.6 million instead of reported $200 million. HighTide Therapeutics is founded by CEO Liping Liu in 2011. HighTide Therapeutics Inc. is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional therapies with poly-indications across metabolic and digestive diseases with significant unmet medical needs.
“ China Biotech Manufacturer HighTide Therapeutics to IPO on Hong Kong Exchange on 22nd December 2023, Target to Raise $35.6 Million Instead of Planned $200 Million “
China Biotech Manufacturer HighTide Therapeutics to IPO on Hong Kong Exchange on 22nd December 2023, Target to Raise $35.6 Million Instead of Planned $200 Million
HighTide Therapeutics
HighTide Therapeutics, Inc. is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional therapies with poly-indications across metabolic and digestive diseases with significant unmet medical needs. The company is developing multiple clinical assets, including therapy for nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC). HTD1801, the company’s lead drug candidate, received Fast Track designation from the U.S. for both NASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project.
Liping Liu, PhD & MBA, Founder & CEO
Since founding HighTide in 2011, Dr. Liping Liu has been primarily responsible for fundraising, overall management of the business strategy, corporate development, and research and development of the Company. Dr. Liu has over 20 years of experience in the R&D of innovative drugs and has accumulated wealthy knowledge and experiences in therapeutic development for metabolic and digestive disease. She has contributed to 8 IND approves in the US, China, Canada, and Australia for two drugs as well as owns over 100 patents and patent applications. Prior to founding HighTide, she served management positions in several U.S. biotech companies, including Associate Director of Antigen Discovery of CTL ImmunoTherapies Corporation, senior R&D manager of MannKind Corporation, head of translational medicine and proteomics department of American Type Culture Collection, Head of Global R&D of Stealth Peptide Inc., and chairwoman of the board of directors and chief scientific officer of ABLE BioGroup LLC., respectively. Dr. Liu received her doctoral degree in Polymer Chemistry and Physics from Nankai University, completed post-doctoral training at the University of Toronto, and obtained an MBA degree from Johns Hopkins University Carey Business School.
Sign Up / Register
Caproasia Users
- Manage $20 million to $3 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
Caproasia Platforms | 11,000 Investors & Advisors
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
Monthly Roundtable & Networking
Family Office Programs
The 2025 Investment Day
- March - Hong Kong
- March - Singapore
- July - Hong Kong
- July - Singapore
- Sept- Hong Kong
- Sept - Singapore
- Oct- Hong Kong
- Nov - Singapore
- Visit: The Investment Day | Register: Click here
Caproasia Summits
- The Institutional Investor Summit
- The Investment / Alternatives Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit
